Cargando…
Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures
OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pil...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262724/ https://www.ncbi.nlm.nih.gov/pubmed/25296098 http://dx.doi.org/10.1097/QAI.0000000000000386 |
_version_ | 1782348457509388288 |
---|---|
author | Baxi, Sanjiv M. Liu, Albert Bacchetti, Peter Mutua, Gaudensia Sanders, Eduard J. Kibengo, Freddie M. Haberer, Jessica E. Rooney, James Hendrix, Craig W. Anderson, Peter L. Huang, Yong Priddy, Frances Gandhi, Monica |
author_facet | Baxi, Sanjiv M. Liu, Albert Bacchetti, Peter Mutua, Gaudensia Sanders, Eduard J. Kibengo, Freddie M. Haberer, Jessica E. Rooney, James Hendrix, Craig W. Anderson, Peter L. Huang, Yong Priddy, Frances Gandhi, Monica |
author_sort | Baxi, Sanjiv M. |
collection | PubMed |
description | OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pill-taking. DESIGN: Participants were randomized to placebo, daily PrEP, or intermittent PrEP to evaluate safety and tolerability of daily versus intermittent tenofovir/emtricitabine (TFV/FTC) in 2 phase II PrEP clinical trials conducted in Africa. Different measures of drug exposure, including self-report, medication event monitoring system (MEMS)-caps openings, and TFV/FTC levels in hair and other biomatrices were compared. METHODS: At weeks 8 and 16, self-reported pill-taking, MEMS-caps openings, and TFV/FTC levels in hair, plasma, and peripheral blood mononuclear cells (PBMCs) were measured. Regression models evaluated predictors of TFV/FTC concentrations in the 3 biomatrices; correlation coefficients between pharmacologic and nonpharmacologic measures were calculated. Both trials were registered on ClinicalTrials.gov (NCT00931346/NCT00971230). RESULTS: Hair collection was highly feasible and acceptable (100% in week 8; 96% in week 16). In multivariate analysis, strong associations were seen between pharmacologic measures and MEMS-caps openings (all P < 0.001); self-report was only weakly associated with pharmacologic measures. TFV/FTC hair concentrations were significantly correlated with levels in plasma and PBMCs (correlation coefficients, 0.41–0.86, all P < 0.001). CONCLUSIONS: Measuring TFV/FTC exposure in small hair samples in African PrEP trials was feasible and acceptable. Hair levels correlated strongly with PBMC, plasma concentrations, and MEMS-caps openings. As in other PrEP trials, self-report was the weakest measure of exposure. Further study of hair TFV/FTC levels in PrEP trials and demonstration projects to assess adherence/exposure is warranted. |
format | Online Article Text |
id | pubmed-4262724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | JAIDS Journal of Acquired Immune Deficiency Syndromes |
record_format | MEDLINE/PubMed |
spelling | pubmed-42627242014-12-16 Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures Baxi, Sanjiv M. Liu, Albert Bacchetti, Peter Mutua, Gaudensia Sanders, Eduard J. Kibengo, Freddie M. Haberer, Jessica E. Rooney, James Hendrix, Craig W. Anderson, Peter L. Huang, Yong Priddy, Frances Gandhi, Monica J Acquir Immune Defic Syndr Clinical Science OBJECTIVE: The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pill-taking. DESIGN: Participants were randomized to placebo, daily PrEP, or intermittent PrEP to evaluate safety and tolerability of daily versus intermittent tenofovir/emtricitabine (TFV/FTC) in 2 phase II PrEP clinical trials conducted in Africa. Different measures of drug exposure, including self-report, medication event monitoring system (MEMS)-caps openings, and TFV/FTC levels in hair and other biomatrices were compared. METHODS: At weeks 8 and 16, self-reported pill-taking, MEMS-caps openings, and TFV/FTC levels in hair, plasma, and peripheral blood mononuclear cells (PBMCs) were measured. Regression models evaluated predictors of TFV/FTC concentrations in the 3 biomatrices; correlation coefficients between pharmacologic and nonpharmacologic measures were calculated. Both trials were registered on ClinicalTrials.gov (NCT00931346/NCT00971230). RESULTS: Hair collection was highly feasible and acceptable (100% in week 8; 96% in week 16). In multivariate analysis, strong associations were seen between pharmacologic measures and MEMS-caps openings (all P < 0.001); self-report was only weakly associated with pharmacologic measures. TFV/FTC hair concentrations were significantly correlated with levels in plasma and PBMCs (correlation coefficients, 0.41–0.86, all P < 0.001). CONCLUSIONS: Measuring TFV/FTC exposure in small hair samples in African PrEP trials was feasible and acceptable. Hair levels correlated strongly with PBMC, plasma concentrations, and MEMS-caps openings. As in other PrEP trials, self-report was the weakest measure of exposure. Further study of hair TFV/FTC levels in PrEP trials and demonstration projects to assess adherence/exposure is warranted. JAIDS Journal of Acquired Immune Deficiency Syndromes 2015-01-01 2014-12-11 /pmc/articles/PMC4262724/ /pubmed/25296098 http://dx.doi.org/10.1097/QAI.0000000000000386 Text en Copyright © 2014 by Lippincott Williams & Wilkins This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Science Baxi, Sanjiv M. Liu, Albert Bacchetti, Peter Mutua, Gaudensia Sanders, Eduard J. Kibengo, Freddie M. Haberer, Jessica E. Rooney, James Hendrix, Craig W. Anderson, Peter L. Huang, Yong Priddy, Frances Gandhi, Monica Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title_full | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title_fullStr | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title_full_unstemmed | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title_short | Comparing the Novel Method of Assessing PrEP Adherence/Exposure Using Hair Samples to Other Pharmacologic and Traditional Measures |
title_sort | comparing the novel method of assessing prep adherence/exposure using hair samples to other pharmacologic and traditional measures |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4262724/ https://www.ncbi.nlm.nih.gov/pubmed/25296098 http://dx.doi.org/10.1097/QAI.0000000000000386 |
work_keys_str_mv | AT baxisanjivm comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT liualbert comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT bacchettipeter comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT mutuagaudensia comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT sanderseduardj comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT kibengofreddiem comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT habererjessicae comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT rooneyjames comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT hendrixcraigw comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT andersonpeterl comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT huangyong comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT priddyfrances comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures AT gandhimonica comparingthenovelmethodofassessingprepadherenceexposureusinghairsamplestootherpharmacologicandtraditionalmeasures |